GSA Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

GSA Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$903K	Buy	+49,177	New	+$792K	0.06%	574
2026 Q1	–	Sell	-25,771	Closed	-$802K	–	2198
2025 Q4	$802K	Buy	+25,771	New	+$707K	0.07%	487
2025 Q1	–	Sell	-11,332	Closed	-$217K	–	2108
2024 Q4	$217K	Buy	+11,332	New	+$246K	0.02%	1374
2023 Q4	–	Sell	-10,844	Closed	-$166K	–	1972
2023 Q3	$166K	Buy	+10,844	New	+$207K	0.01%	1321
2020 Q4	–	Sell	-1,288	Closed	-$15K	–	1633
2020 Q3	$15K	Buy	+1,288	New	+$19.2K	﹤0.01%	1218

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GSA Capital Partners's VRDN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 49,177 shares worth $903K. The stake represents 0.06% of the portfolio and ranks #574 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in VRDN as recently as Q4 2025.

GSA Capital Partners first reported a position in VRDN in Q3 2020 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

GSA Capital Partners held 49,177 shares of Viridian Therapeutics worth $903K as of Q2 2026.
Viridian Therapeutics was a new GSA Capital Partners position in Q2 2026.
Viridian Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #574 holding.
GSA Capital Partners first reported a position in Viridian Therapeutics in Q3 2020 and has held it in 5 quarters since.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.